CH274233A - Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxy group in ring C. - Google Patents
Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxy group in ring C.Info
- Publication number
- CH274233A CH274233A CH274233DA CH274233A CH 274233 A CH274233 A CH 274233A CH 274233D A CH274233D A CH 274233DA CH 274233 A CH274233 A CH 274233A
- Authority
- CH
- Switzerland
- Prior art keywords
- sep
- acid
- compound
- ring
- oxy group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 title description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 2
- 239000002253 acid Substances 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 150000004702 methyl esters Chemical class 0.000 claims description 4
- 239000012433 hydrogen halide Substances 0.000 claims description 3
- 229910000039 hydrogen halide Inorganic materials 0.000 claims description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 150000003944 halohydrins Chemical class 0.000 claims description 2
- 239000013067 intermediate product Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229930194542 Keto Natural products 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Verfahren zur Herstellung einer in Ring C eine Oxygruppe enthaltenden Verbindung der Cyelopentanopolyhydrophenanthren-Reihe. (;egenstand der Erfindung ist.
ein Ver fahren zur Herstellung einer im Ring C eine Oxygruppe enthaltenden Verbindung der Cy- elopent.anopolyhydi@ophena.utliren-Reihe, wel- ehes dadurch gekennzeielinet ist, da.ss der d> >>>z - 3 - lieto - eholensäure - methylester vom Sehml)
. 120-12" C durch Anlagerung von unterhalogeniger Säure in ein Halogenhydrin und dieses durch Entzug; von Halogen wasserstoff in den 11,1\)ss - Ozydo - 3 - ket.o- cliolaiisäure-inethylester übergeführt, das eben benannte Zwischenprodukt sodann hydriert.
und das erhaltene Reaktionsprodukt. durch Acetylierung in den 3-Aeetoxy-Ilss-liydroxy- eliolansäure-inethylester vom Sehnip. 1.46 bis 1-18" C übergeführt. wird. Das erfindungsgemässe Verfahren liefert ein zur Synthese von Hormonen der Neben nierenrinde wichtiges Produkt.
Bei der Durchführung des erfindungs- bemässen Verfahrens wird die unterhalo- genibe Säure vorzugsweise in Gegenwart des Ausgangsstoffes aus Stoffen, welche mit Wasser unterhalogenige Säure abgeben, wie beispielsweise Bromaeetamid oder Chloramin, hergestellt. Die erhaltenen pIalogenhydrine werden z. B. mit halogenwasserstoffabspalten- den Mitteln, wie z.
B. Alkalilauge oder insbe sondere Aluminiumoxyd, in den 11.,12ss- Ox37do-3-keto-eholansänre-inethylester über- geführt. Die Acetyliernnb erfolgt zweckmässig durch Behandlung mit Aeetanhy drill und Py ridin.
EMI0001.0065
EMI0002.0001
<I>Beispiel:
</I>
<tb> 500 <SEP> mg <SEP> A".ia_3-h'eto-cholensäure-metIiyl ester <SEP> vom <SEP> Schmp. <SEP> 120-1)2 <SEP> C <SEP> wurden <SEP> in
<tb> 40 <SEP> cm3 <SEP> Aeeton <SEP> aufgelöst, <SEP> die <SEP> Lösung <SEP> mit
<tb> 350 <SEP> mg <SEP> Bromacetamid <SEP> (2 <SEP> 1GIol) <SEP> und <SEP> 10 <SEP> cm@
<tb> Wasser <SEP> versetzt <SEP> und <SEP> bei <SEP> Zimmertemperatur
<tb> 16 <SEP> Stunden <SEP> stehengelassen. <SEP> Nach <SEP> Zusatz <SEP> von
<tb> Wasser <SEP> wurde <SEP> das <SEP> Aceton <SEP> im <SEP> Vakuum <SEP> ent fernt <SEP> und <SEP> der <SEP> Rückstand <SEP> mit <SEP> Äther <SEP> ausge zogen. <SEP> Die <SEP> Ätherlösung <SEP> wurde <SEP> mit <SEP> verdünn ter <SEP> Soda.lösung <SEP> und <SEP> mit <SEP> Wasser <SEP> gewaschen,
<tb> über <SEP> Natriumsulfat <SEP> getrocknet <SEP> und <SEP> einge dampft.
<SEP> Der <SEP> Rückstand <SEP> wurde <SEP> an <SEP> 20 <SEP> g <SEP> Alu miniumoxyd <SEP> ehromatographiert. <SEP> Die <SEP> mit
<tb> Benzol <SEP> sowie <SEP> mit <SEP> Benzol-tither <SEP> (50:1) <SEP> eluier baren <SEP> Anteile <SEP> lieferten <SEP> den <SEP> 3-Iieto-11,12-di brom-cholansäure-methylester <SEP> in <SEP> farblosen
<tb> Nadeln <SEP> vom <SEP> Sehmp. <SEP> 136-138 <SEP> C <SEP> nach <SEP> Um kristallisation <SEP> aus <SEP> Äther-Pet.roläther. <SEP> Hieraus
<tb> wurde <SEP> durch <SEP> Entbromung <SEP> der <SEP> Ausgangsstoff
<tb> zurückgewonnen.
<SEP> Weitere <SEP> mit <SEP> Benzol-lither Gemischen <SEP> von <SEP> steigendem <SEP> Ätlierg-ehalt <SEP> so wie <SEP> mit <SEP> reinem <SEP> Äther <SEP> eluierte <SEP> Fraktionen
<tb> lieferten <SEP> nach <SEP> Umkristallisation <SEP> aus <SEP> Pet.rol äther <SEP> den <SEP> 11,12ss-Otydo-3-keto-eliolailsäure methy <SEP> lester <SEP> der <SEP> Formel <SEP> II.
<tb>
Die <SEP> weiteren <SEP> mit. <SEP> Äther-Methanol <SEP> (9:1)
<tb> eluierten <SEP> Anteile <SEP> lieferten <SEP> durch <SEP> <B>Ox-</B> <SEP> ydation
<tb> mit <SEP> Chromsäure <SEP> und <SEP> Entbromen <SEP> mit <SEP> Zink staub <SEP> den <SEP> .d9#11-3,1?-Diketo-eholensäure-me thylester.
<tb>
Das <SEP> Oxyd <SEP> der <SEP> Formel <SEP> II <SEP> wurde <SEP> hydriert
<tb> und <SEP> das <SEP> erhaltene <SEP> Reduktionsprodukt <SEP> bei
<tb> Zimmertemperatur <SEP> mit <SEP> Acetanhydrid <SEP> und
<tb> Pyridin <SEP> behandelt. <SEP> Nach <SEP> einer <SEP> üblichen <SEP> Me thode <SEP> aufgearbeitet, <SEP> wurde <SEP> der <SEP> 3-Acetoxy-llss liydroxy-eholansäure-metliylester <SEP> der <SEP> Formel
<tb> III <SEP> in <SEP> langen <SEP> Nadeln <SEP> vom <SEP> Sehmp. <SEP> 146 <SEP> bis
<tb> 14-8 <SEP> C <SEP> erhalten. <SEP> Die <SEP> spezifische <SEP> Drehung
<tb> betrug <SEP> [a] <SEP> D <SEP> = <SEP> 70,7 <SEP> <SEP> 2 <SEP> (e <SEP> = <SEP> 1,018 <SEP> in
<tb> Aceton).
EMI0002.0002
Als <SEP> Nebenprodukt <SEP> wurde <SEP> der <SEP> in <SEP> 3 <SEP> Stel lung <SEP> stereoisomere <SEP> Ester <SEP> vom <SEP> Sehnip. <SEP> 1-11 <SEP> bis
<tb> 142 <SEP> C <SEP> mit <SEP> der <SEP> spez. <SEP> Drehun,- <SEP> [a]D <SEP> = <SEP> + <SEP> 50"
<tb> (Aeetoii) <SEP> erhalten.
Process for the preparation of a compound of the cyelopentanopolyhydrophenanthrene series containing an oxy group in ring C. (; subject of the invention.
a process for the production of a compound of the cyelopent.anopolyhydi@ophena.utliren- series which contains an oxy group in ring C, which is characterized by the fact that the d >>> z - 3 - lieto - eholenic acid - methyl ester from Sehml)
. 120-12 "C by the addition of hypohalous acid into a halohydrin and this by withdrawal; of hydrogen halide converted into the 11.1 \) ss - ozydo - 3 - ket.oclonalic acid methyl ester, the intermediate product just mentioned is then hydrogenated.
and the obtained reaction product. by acetylation in the 3-ethoxy-Ilss-liydroxy-eliolansäure-inethylester from Sehnip. 1.46 to 1-18 "C. The process according to the invention provides a product which is important for the synthesis of hormones of the adrenal cortex.
When carrying out the process according to the invention, the hypohalous acid is preferably prepared in the presence of the starting material from substances which give off hypohalous acid with water, such as bromaeetamide or chloramine, for example. The pIalogenhydrins obtained are z. B. with hydrogen halide splitting agents such.
B. alkali or in particular special aluminum oxide, converted into the 11th, 12ss-Ox37do-3-keto-eholansänre-inethylester. The acetylation is expediently carried out by treatment with Aeetanhy drill and pyridine.
EMI0001.0065
EMI0002.0001
<I> example:
</I>
<tb> 500 <SEP> mg <SEP> A ".ia_3-h'eto-cholenic acid-methyl ester <SEP> from <SEP> mp <SEP> 120-1) 2 <SEP> C <SEP> were < SEP> in
<tb> 40 <SEP> cm3 <SEP> Aeeton <SEP> dissolved, <SEP> the <SEP> solution <SEP> with
<tb> 350 <SEP> mg <SEP> bromoacetamide <SEP> (2 <SEP> 1GIol) <SEP> and <SEP> 10 <SEP> cm @
<tb> water <SEP> adds <SEP> and <SEP> at <SEP> room temperature
<tb> 16 <SEP> hours <SEP> left. <SEP> after <SEP> addition <SEP> of
<tb> water <SEP> was <SEP> the <SEP> acetone <SEP> in the <SEP> vacuum <SEP> removed <SEP> and <SEP> the <SEP> residue <SEP> with <SEP> ether < SEP> moved out. <SEP> The <SEP> ether solution <SEP> was washed <SEP> with <SEP> diluted <SEP> soda solution <SEP> and <SEP> with <SEP> water <SEP>,
<tb> dried over <SEP> sodium sulfate <SEP> <SEP> and <SEP> evaporated.
<SEP> The <SEP> residue <SEP> was <SEP> etomatographed on <SEP> 20 <SEP> g <SEP> aluminum oxide <SEP>. <SEP> The <SEP> with
<tb> Benzene <SEP> and <SEP> with <SEP> Benzene-tither <SEP> (50: 1) <SEP> elutable <SEP> parts <SEP> provided <SEP> the <SEP> 3-Iieto- 11,12-di-bromocholanic acid methyl ester <SEP> in <SEP> colorless
<tb> needles <SEP> from <SEP> Sehmp. <SEP> 136-138 <SEP> C <SEP> after <SEP> Recrystallization <SEP> from <SEP> ether-pet.rolether. <SEP> From this
<tb> <SEP> became <SEP> the <SEP> starting material through <SEP> Entbromung <SEP>
<tb> recovered.
<SEP> Further <SEP> with <SEP> benzene-lither mixtures <SEP> of <SEP> increasing <SEP> etching content <SEP> as well as <SEP> with <SEP> pure <SEP> ether <SEP> eluted <SEP> political groups
<tb> <SEP> after <SEP> recrystallization <SEP> from <SEP> Pet.rol ether <SEP> delivered the <SEP> 11,12ss-Otydo-3-keto-eliolailic acid methy <SEP> lester <SEP> der <SEP> Formula <SEP> II.
<tb>
The <SEP> other <SEP> with. <SEP> ether-methanol <SEP> (9: 1)
<tb> eluted <SEP> parts <SEP> delivered <SEP> through <SEP> <B> Ox- </B> <SEP> ydation
<tb> with <SEP> chromic acid <SEP> and <SEP> Entbromen <SEP> with <SEP> zinc dust <SEP> the <SEP> .d9 # 11-3,1? -diketo-eholenic acid methyl ester.
<tb>
The <SEP> oxide <SEP> of the <SEP> formula <SEP> II <SEP> was <SEP> hydrogenated
<tb> and <SEP> the <SEP> obtained <SEP> reduction product <SEP>
<tb> room temperature <SEP> with <SEP> acetic anhydride <SEP> and
<tb> Pyridine <SEP> treated. <SEP> After <SEP> a <SEP> common <SEP> method <SEP> worked up, <SEP> was <SEP> the <SEP> 3-acetoxy-llss liydroxy-eholanoic acid methyl ester <SEP> the <SEP> formula
<tb> III <SEP> in <SEP> long <SEP> needles <SEP> from <SEP> Sehmp. <SEP> 146 <SEP> to
<tb> 14-8 <SEP> C <SEP> received. <SEP> The <SEP> specific <SEP> rotation
<tb> was <SEP> [a] <SEP> D <SEP> = <SEP> 70.7 <SEP> <SEP> 2 <SEP> (e <SEP> = <SEP> 1.018 <SEP> in
<tb> acetone).
EMI0002.0002
The <SEP> by-product <SEP> was <SEP> the <SEP> in <SEP> 3 <SEP> position <SEP> stereoisomeric <SEP> ester <SEP> of the <SEP> sehnip. <SEP> 1-11 <SEP> to
<tb> 142 <SEP> C <SEP> with <SEP> the <SEP> spec. <SEP> Turn, - <SEP> [a] D <SEP> = <SEP> + <SEP> 50 "
<tb> (Aeetoii) <SEP> received.
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH274233T | 1942-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH274233A true CH274233A (en) | 1951-03-31 |
Family
ID=4479649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH274233D CH274233A (en) | 1942-06-24 | 1942-06-24 | Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxy group in ring C. |
Country Status (1)
| Country | Link |
|---|---|
| CH (1) | CH274233A (en) |
-
1942
- 1942-06-24 CH CH274233D patent/CH274233A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE895453C (en) | Process for the production of 7-dehydrosterols, in particular 7-dehydrocholesterol | |
| CH274233A (en) | Process for the preparation of a compound of the cyclopentanopolyhydrophenanthrene series which contains an oxy group in ring C. | |
| DE1214226B (en) | Process for the preparation of 6-chloro-3-keto-delta 4,6-steroids of the androstane or egnane series | |
| DE825686C (en) | Process for the conversion of í¸-20-cyanpregnenes with one or more nucleus-bound hydroxyl groups into 17 alpha-oxy-20-ketopregnanes | |
| DE965326C (en) | Process for the preparation of 23-bromo-5ª ‡, 22-a-spirostan-3ª ‰, 12ª ‰ -diol-11-one | |
| DE2016783C3 (en) | Process for converting a 17β-hydroxy steroid into the corresponding 17α-hydroxy compound | |
| AT224821B (en) | Process for the preparation of Δ1, 4-pregnadiene-17α, 21-diol-3, 20-dione | |
| DE964677C (en) | Process for the production of allopregnans | |
| DE842490C (en) | Process for the production of steroid-17-carboxylic acids | |
| AT229497B (en) | Process for the preparation of 9-halo-1, 4-pregnadien-11-ols | |
| DE965238C (en) | Process for the production of pregnans unsaturated in the 11 (12) position | |
| CH284986A (en) | Process for the preparation of a derivative of pregnane-3,11,20-trione. | |
| AT243447B (en) | Process for the preparation of 16-pregnenes oxygenated in position 11 | |
| DE843411C (en) | Process for the production of pregnane derivatives substituted in the 21-position | |
| DE1813998C3 (en) | Process for the preparation of 3-methoxy-18-methyl-1,3,5 (10), 6,8-oestrapentaen-17-one | |
| AT251774B (en) | Process for the production of new 6α9α-difluoro-16-methylpregnenes and -pregnadienes | |
| CH513836A (en) | Cyclopentanophenanthrene derivs | |
| DE1094258B (en) | Process for the preparation of fluorinated 16-methyl steroids | |
| DE1113453B (en) | Process for the production of substitution products of Reichsteins-Substance-S or their 21-acylates | |
| DE1145170B (en) | Process for the preparation of 9,11-oxidosteroids of the androstane and pregnane series | |
| CH377342A (en) | Process for the preparation of 20-monoenol acylates of 11,20-diketosteroids | |
| DE1042580B (en) | Process for the production of unsaturated compounds of the cyclopentane poly-hydrophenanthrene series | |
| DE1002352B (en) | Process for the preparation of 16ª ‡, 20ª ‡ -dihydroxysteroids | |
| DE1173895B (en) | Process for the preparation of 17-oxygenated derivatives of 19-nor-4-androsten-3-one substituted in the 4-position | |
| DD144548A1 (en) | PROCESS FOR PREPARATION OF PREGNA-1,4-DIEN-3,20-DION |